Three-month evaluation of dorzolamide hydrochloride/timolol maleate fixed-combination eye drops versus the separate use of both drugs

Japanese Journal of Ophthalmology

Volumn 56, Issue 6, 2012, Pages 559-563

  Inoue, Kenji ^a   Shiokawa, Minako ^a   Sugahara, Michitaka ^a   Wakakura, Masato ^a   Soeda, Shoichi ^a   Tomita, Goji ^b  

^a Inoue Eye Hospital   (Japan)

^b TOHO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Adherence; Adverse reactions; Dorzolamide hydrochloride 1 timolol maleate 0.5 combination; Intraocular pressure; Switch

Indexed keywords

BUNAZOSIN; DIPIVEFRINE; DORZOLAMIDE; DORZOLAMIDE PLUS TIMOLOL; EYE DROPS; LATANOPROST; TAFLUPROST; TIMOLOL; TIMOLOL MALEATE; TRAVOPROST;

ADULT; AGED; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; BITTER TASTE; BLURRED VISION; BURNING SENSATION; CLINICAL ARTICLE; CLINICAL EVALUATION; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DRY EYE; EVENING DOSAGE; EYE DISCOMFORT; EYE IRRITATION; FEMALE; HUMAN; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; LOW TENSION GLAUCOMA; MALE; MORNING DOSAGE; OCULAR PRURITUS; OPEN ANGLE GLAUCOMA; PATIENT COMPLIANCE; PRIORITY JOURNAL; QUESTIONNAIRE; SIDE EFFECT; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTIHYPERTENSIVE AGENTS; DRUG COMBINATIONS; DRUG EVALUATION; DRUG THERAPY, COMBINATION; FEMALE; GLAUCOMA, OPEN-ANGLE; HUMANS; INTRAOCULAR PRESSURE; MALE; MEDICATION ADHERENCE; MIDDLE AGED; OCULAR HYPERTENSION; OPHTHALMIC SOLUTIONS; QUESTIONNAIRES; SULFONAMIDES; THIOPHENES; TIMOLOL; TONOMETRY, OCULAR;

EID: 84872203325     PISSN: 00215155     EISSN: 16132246     Source Type: Journal    
DOI: 10.1007/s10384-012-0186-8     Document Type: Article

References (18)

1. Collaborative Normal-Tension Glaucoma Study Group. The effectiveness of intraocular pressure reduction in the treatment of normal-tension glaucoma. Am J Ophthalmol. 1998;126:498-505.
2. The AGIS Investigators. The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. Am J Ophthalmol. 2000; 130:429-40.
3. Djafari F, Lesk MR, Harasymowycz PJ, Desjardins D, Lachaine J. Determinants of adherence to glaucoma medical therapy in a long-term patient population. J Glaucoma. 2009;18:238-42.
4. Choudhri S, Wand M, Shields MB. A comparison of dorzolamide-timolol combination versus the concomitant drugs. Am J Ophthalmol. 2000;130:832-3. (Pubitemid 32000869)
5. Strohmaier K, Snyder E, Dubiner H, Adamsons I, The Dorzolamide-Timolol Study Group. The efficacy and safety of the dorzolamide-timolol combination versus the concomitant administration of its components. Ophthalmology. 1998;105:1936-44. (Pubitemid 28509737)
6. Parmaksiz S, Yüksel N, Karabas VL, Özkan B, Demirci G, Caglar Y. A comparison of travoprost, latanoprost, and the fixed combination of dorzolamide and timolol in patients with pseudoexfolitation glaucoma. Eur J Ophthalmol. 2006;16:73-80.
7. Konstas AGP, Papapanos P, Tersis I, Houliara D, Stewart WC. Twenty-four-hour diurnal curve comparison of commercially available latanoprost 0.005% versus the timolol and dorzolamide fixed combination. Ophthalmology. 2003;110:1357-60. (Pubitemid 36842471)
8. Orzalesi N, Rossetti L, Bottoli A, Fumagalli E, Fogagnolo P. The effect of latanoprost, bimonidine, and a fixed combination of timolol and dorzolamide on circadian intraocular pressure in patients with glaucoma or ocular hypertension. Arch Ophthalmol. 2003;121:453-7. (Pubitemid 36427631)
9. Janulevicienë I, Harris A, Kagemann L, Siesky B, McCranor L. A comparison of the effects of dorzolamide/timolol fixed combination versus latanoprost on intraocular pressure and pulsatile ocular blood flow in primary open-angle glaucoma patients. Acta Ophthalmol Scand. 2004;82:730-7. (Pubitemid 40057785)
10. Mulaney J, Sonty S, Ahmad A, Stewart JA, Stewart WC. Comparison of daytime efficacy and safety of dorzolamide/timolol maleate fixed combination versus latanoprost. Eur J Ophthalmol. 2008;18:556-62.
11. Konstas AGP, Kozobolis VP, Tsironi S, Makridaki I, Efremova R, Stewart WC. Comparison of the 24-hour intraocular pressurelowering effects of latanoprost and dorzolamide/timolol fixed combination after 2 and 6 months of treatment. Ophthalmology. 2008;115:99-103.
12. Fechtner RD, Airaksinen PJ, Getson AJ, Lines CR, Adamsons IA. on behalf of the COSOPT versus XALATAN Study Groups. Efficacy and tolerability of the dorzolamide 2%/timolol 0.5% combination (COSOPT™) versus latanoprost 0.005% (XALATAN™) in the treatment of ocular hypertension or glaucoma: results from two randomized clinical trials. Acta Ophthalmol Scand. 2004;82:42-8. (Pubitemid 38228661)
13. Konstas AGP, Kozobolis VP, Tersis I, Leech J, Stewart WC. The efficacy and safety of the timolol/dorzolamide fixed combination vs latanoprost in exfoliation glaucoma. Eye. 2003;17:41-6. (Pubitemid 36181837)
14. Honrubia FM, Larsson LI, Spiegel D, The European Latanoprost Study Group. A comparison of the effects on intraocular pressure of latanoprost 0.005% and the fixed combination of dorzolamide 2% and timolol 0.5% in patients with open-angle glaucoma. Acta Ophthalmol Scand. 2002;80:635-41. (Pubitemid 36024478)
15. Kitazawa Y, Araie M, Research Group on MK-0507A. Double-masked, phase III comparative study of the combination ophthalmic solution of the 1% dorzolamide hydrochloride/0.5% timolol maleate (MK-0507A) in patients with glaucoma and ocular hypertension. Nippon Ganka Gakkai Zasshi. 2011;115:495-507.
16. Kitazawa Y, Azuma I, Iwata K, Tsukahara S, Shiose Y, Araie M, et al. Dorzolamide, a topical carbonic anhydrase inhibitor: a twoweek dose-response study in patients with glaucoma or ocular hypertension. J Glaucoma. 1994;3:275-9.
17. Mizoguchi T, Ozaki M, Wakiyama H, Ogino N. Additive intraocular pressure-lowering effect of dorzolamide 1%/timolol 0.5% fixed combination on prostaglandin monotherapy in patients with normal tension glaucoma. Clin Ophthalmol. 2011;5:1515-20.
18. Inoue K, Okugawa K, Oshika T, Amano S. Influence of dorzolamide on corneal endothelium. Jpn J Ophthalmol. 2003;47:129-33. (Pubitemid 36547820)